It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CMOPF’s FA Score shows that 1 FA rating(s) are green whileDSNKY’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CMOPF’s TA Score shows that 1 TA indicator(s) are bullish while DSNKY’s TA Score has 3 bullish TA indicator(s).
CMOPF (@Pharmaceuticals: Major) experienced а -3.87% price change this week, while DSNKY (@Pharmaceuticals: Major) price change was -6.41% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.43%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.91%.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
CMOPF | DSNKY | CMOPF / DSNKY | |
Capitalization | 828M | 59.2B | 1% |
EBITDA | 42.1M | 203B | 0% |
Gain YTD | 27.113 | 2.027 | 1,337% |
P/E Ratio | 68.49 | 75.76 | 90% |
Revenue | 104M | 1.28T | 0% |
Total Cash | 222M | 825B | 0% |
Total Debt | 176M | 143B | 0% |
CMOPF | DSNKY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 71 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 61 | |
SMR RATING 1..100 | 56 | 2 | |
PRICE GROWTH RATING 1..100 | 64 | 78 | |
P/E GROWTH RATING 1..100 | 100 | 91 | |
SEASONALITY SCORE 1..100 | 30 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CMOPF's Valuation (16) in the null industry is in the same range as DSNKY (31). This means that CMOPF’s stock grew similarly to DSNKY’s over the last 12 months.
DSNKY's Profit vs Risk Rating (61) in the null industry is somewhat better than the same rating for CMOPF (100). This means that DSNKY’s stock grew somewhat faster than CMOPF’s over the last 12 months.
DSNKY's SMR Rating (2) in the null industry is somewhat better than the same rating for CMOPF (56). This means that DSNKY’s stock grew somewhat faster than CMOPF’s over the last 12 months.
CMOPF's Price Growth Rating (64) in the null industry is in the same range as DSNKY (78). This means that CMOPF’s stock grew similarly to DSNKY’s over the last 12 months.
DSNKY's P/E Growth Rating (91) in the null industry is in the same range as CMOPF (100). This means that DSNKY’s stock grew similarly to CMOPF’s over the last 12 months.
CMOPF | DSNKY | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago81% |
Stochastic ODDS (%) | N/A | 2 days ago72% |
Momentum ODDS (%) | 2 days ago13% | 2 days ago72% |
MACD ODDS (%) | 2 days ago19% | 2 days ago67% |
TrendWeek ODDS (%) | 2 days ago18% | 2 days ago68% |
TrendMonth ODDS (%) | 2 days ago17% | 2 days ago70% |
Advances ODDS (%) | N/A | 16 days ago70% |
Declines ODDS (%) | N/A | 3 days ago68% |
BollingerBands ODDS (%) | N/A | 2 days ago81% |
Aroon ODDS (%) | N/A | 2 days ago70% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
VECRX | 21.33 | N/A | N/A |
Virtus KAR Equity Income R6 | |||
FIQPX | 50.77 | -0.04 | -0.08% |
Fidelity Advisor Emerging Asia Z | |||
JGSRX | 12.35 | -0.06 | -0.48% |
JHancock Global Shareholder Yield R2 | |||
GQSCX | 14.69 | -0.14 | -0.94% |
Glenmede Quant US Small Cap Equity | |||
VVOCX | 19.58 | -0.41 | -2.05% |
Invesco Value Opportunities C |
A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.
Ticker / NAME | Correlation To CMOPF | 1D Price Change % | ||
---|---|---|---|---|
CMOPF | 100% | -3.87% | ||
GSK - CMOPF | 22% Poorly correlated | +1.94% | ||
NVS - CMOPF | 21% Poorly correlated | +1.36% | ||
CHGCY - CMOPF | 7% Poorly correlated | +3.71% | ||
DSNKY - CMOPF | 5% Poorly correlated | +0.62% | ||
CSPCY - CMOPF | 4% Poorly correlated | +0.56% | ||
More |
A.I.dvisor indicates that over the last year, DSNKY has been loosely correlated with CHGCY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if DSNKY jumps, then CHGCY could also see price increases.
Ticker / NAME | Correlation To DSNKY | 1D Price Change % | ||
---|---|---|---|---|
DSNKY | 100% | +0.62% | ||
CHGCY - DSNKY | 38% Loosely correlated | +3.71% | ||
OTSKY - DSNKY | 37% Loosely correlated | -1.45% | ||
DSKYF - DSNKY | 34% Loosely correlated | -5.06% | ||
BIIB - DSNKY | 23% Poorly correlated | +0.10% | ||
ALPMY - DSNKY | 21% Poorly correlated | -0.30% | ||
More |